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ABSTRACT
Background
It has been suggested throughout the past fifty years that serum uric acid concentrations can
help predict the future risk of coronary heart disease (CHD), but the epidemiological evidence is
uncertain.
Methods and Findings
We report a ‘‘nested’’ case-control comparison within a prospective study in Reykjavik,
Iceland, using baseline values of serum uric acid in 2,456 incident CHD cases and in 3,962 age-
and sex-matched controls, plus paired serum uric acid measurements taken at baseline and, on
average, 12 y later in 379 participants. In addition, we conducted a meta-analysis of 15 other
prospective studies in eight countries conducted in essentially general populations. Compared
with individuals in the bottom third of baseline measurements of serum uric acid in the
Reykjavik study, those in the top third had an age- and sex-adjusted odds ratio for CHD of 1.39
(95% confidence interval [CI], 1.23–1.58) which fell to 1.12 (CI, 0.97–1.30) after adjustment for
smoking and other established risk factors. Overall, in a combined analysis of 9,458 cases and
155,084 controls in all 16 relevant prospective studies, the odds ratio was 1.13 (CI, 1.07–1.20),
but it was only 1.02 (CI, 0.91–1.14) in the eight studies with more complete adjustment for
possible confounders.
Conclusions
Measurement of serum uric acid levels is unlikely to enhance usefully the prediction of CHD,
and this factor is unlikely to be a major determinant of the disease in general populations.
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Numerous genetic and environmental factors have been
associated with uric acid [1], and serum uric acid values are
markedly elevated in patients with gout (Table 1). Since at
least ﬁfty years ago, modestly higher serum uric acid
concentrations have been reported in patients with coronary
heart disease (CHD) than in controls [2], and there have been
suggestions that measurement of serum uric acid can enhance
the prediction of CHD [3]. Prospective epidemiological
studies have, however, reported apparently conﬂicting ﬁnd-
ings, with several studies reporting positive associations only
among women [4,5], The interpretation of the data has been
further complicated by the correlation of serum uric acid
concentrations with several established coronary risk factors
(such as blood pressure), with the use of cardiovascular
medications (such as diuretics), and with clinical conditions
associated with CHD (such as chronic renal disease [6]). It has
been difﬁcult, therefore, to determine whether serum uric
acid values are predictive of CHD, and, if so, whether any
such associations are independent from established risk
factors or from the effects of disease or both.
To help address these uncertainties, we report a prospec-
tive study with more CHD cases than any previous report on
serum uric acid, involving 2,459 incident cases of nonfatal
myocardial infarction (MI) and CHD death, and 3,969
controls from within a prospective observational study of
about 19,000 middle-aged Icelanders without a previous
history of MI. To help put these results in context, we also
report a meta-analysis of 15 previously published prospective
studies of serum uric acid, involving a total of an additional
7,002 incident CHD cases and an additional 151,122 controls,
including supplementary information obtained by corre-
spondence from investigators to help assess in more detail the
impact of possible confounders. The present analyses have
been restricted to prospective cohorts sampled from essen-
tially general populations (i.e., excluding cohorts selected on
the basis of existing vascular or other diseases, or on the basis
of having risk factors for vascular disease, such as high blood
pressure) to reduce any distorting effects of preexisting
disease on serum uric acid levels.
Methods
The Reykjavik Study
The Reykjavik Study, initiated in 1967 as a prospective
study of cardiovascular disease, has been described in detail
previously [7]. All men born between 1907 and 1934 and all
women born between 1908 and 1935 who were resident in
Reykjavik, Iceland, and its adjacent communities on 01
December 1966 were identiﬁed in the national population
register and then invited to participate in the Reykjavik Study
during ﬁve stages of recruitment between 1967 and 1991,
yielding 8,888 male and 9,681 female participants without a
history of MI (72% response rate). Nurses administered
questionnaires, made physical measurements, recorded an
electrocardiogram, performed spirometry, and collected
fasting venous blood samples, which were stored at  20 8C
for subsequent analysis. All participants have been monitored
subsequently for all-cause mortality and for cardiovascular
morbidity, with a loss to follow-up of less than 1% to date. A
total of 2,459 men and women with available serum samples
had major coronary events between the beginning of follow-
up and 31 December 1995, yielding mean durations of follow-
up among CHD cases of 17.5 (standard deviation [SD] 8.7)
years and, among controls, of 20.6 (SD, 8.2) years. In total,
1,073 CHD deaths and 701 nonfatal MIs were recorded
among men (including 564 conﬁrmed MIs and 137 possible
MIs), and 385 CHD deaths and 300 nonfatal MIs among
women (including 237 conﬁrmed MIs and 63 possible MIs).
Deaths from coronary heart disease were ascertained from
central registers on the basis of a death certiﬁcate with
International Classiﬁcation of Diseases codes 410–414, and
the diagnosis of nonfatal MI was based on MONICA criteria.
We selected 3,969 controls that were ‘‘frequency-matched’’ to
cases on calendar year of recruitment, sex, and age in 5-y
bands from among participants who had survived to the end
of the study period without a MI. The National Bioethics
Committee and the Data Protection Authority of Iceland
approved the study protocol, and participants provided
informed consent.
Laboratory Methods
Serum uric acid levels were measured with a Technicon
autoanalyzer [8]. The measurement of other biochemical
analytes has been described previously [7]. Baseline measure-
ments of serum uric acid were available on 2,456 out of 2,459
CHD cases and 3,962 out of 3,969 controls. To assess the
within-person consistency of serum uric acid levels over time,
measurements were made in pairs of samples collected at an
interval of about 12 y apart in 379 individuals in the present
study.
Statistical Methods and Meta-Analysis
Case-control comparisons were made by unmatched
stratiﬁed logistic regression ﬁtted by unconditional maxi-
mum likelihood. Analysis of serum uric acid values was
previously speciﬁed to be by sex-speciﬁc thirds of values in
the controls (with subsidiary analyses involving other cut-off
values). Adjustment was made for age, sex, smoking status
Table 1. Characteristics of Uric Acid
Feature Characteristic
Description End point of purine metabolism in humans. The major-
ity of uric acid is reabsorbed by the kidney, while the
remainder is excreted in urine. Over- or underproduc-
tion of uric acid may cause gouty arthritis.
Vascular effects None directly established but suggested mechanisms
include: formation of free radicals; enhanced platelet
adhesiveness and aggregation; oxidation of LDL; renal
involvement in hypertension
Main site of synthesis Liver
Main correlates Male sex; blood pressure, lipids (in particular triglycer-
ides); antihypertensive treatment; history of CHD; obe-
sity; high-purine diet; alcohol intake; insulin resistance;
black ethnicity; menopause
Baseline serum
concentration
a
Men: 320 (70) lmol/l; (5.4 [1.1] mg/dl
b); women: 270
(70) lmol/l; (4.5 [1.1] mg/dl
b)
Self-correlation
c 0.6
a Values are mean (SD)
b Conversion to SI units: 1 lmol/l = 59.48 mg/dl
c Approximate correlation between two measurements taken some years apart in the same individuals.
DOI: 10.1371/journal.pmed.0020076.t001
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Serum Uric Acid: Prospective Study(never, former, current), daily cigarette consumption, blood
pressure, body mass index, fasting concentrations of total
cholesterol and triglycerides, and various markers of socio-
economic status related to occupation, education, home
ownership, and type of accommodation. We assessed varia-
tion in the strength of association according to pre-speciﬁed
sub-groups, using likelihood ratio tests for interaction after
adjusting for these factors, with 99% conﬁdence intervals
(CIs) used in these exploratory analyses.
For the meta-analysis, studies of serum uric acid and CHD
published before May 2003 with greater than a year’s follow-
up conducted in essentially general populations (i.e.,
excluding cohorts deﬁned on the basis of preexisting
cardiovascular or other diseases) were sought by computer-
based searches, scanning the reference lists of all relevant
studies and review articles, hand-searching of relevant
journals, and correspondence with authors of studies.
Computer searches using Medline, PubMed, Web of Science,
and Embase databases used keywords relating to uric acid in
combination with CHD (e.g., coronary heart disease,
ischemic heart disease, vascular disease, MI, and atheroscle-
rosis). Relevant endpoints included nonfatal MI (generally
using World Health Organization criteria) and CHD death
(generally using International Classiﬁcation of Disease
criteria).
The following factors were abstracted from each study:
numbers of cases and controls, mean age of cases and
percentage of males, mean duration of follow-up, assay type,
and those used for adjustment in multivariable assessments.
Five studies were excluded because they reported insufﬁcient
data or only unadjusted risk ratios [9,10,11,12,13], but these
involved only a total of about 590 CHD cases (or , 6% of the
total number of cases in the present report). Of 16 studies
(including four studies that had not previously reported in
relation to CHD [14,15,16,17]), 11 provided supplementary
tabular data on sex-speciﬁc ‘‘relative risks’’ (i.e., incidence
rate ratios according to sex-speciﬁc thirds of serum uric acid
distribution in controls) and details of factors adjusted for in
multivariable analyses. We excluded female-speciﬁc estimates
based on fewer than 30 CHD cases, owing to very small
sample sizes from two studies [16,18]. Where data were not
available by thirds of serum uric acid levels, the log-relative
risk (and its standard error) was estimated from the reported
relative risks using log-linear scaling and assuming normality
of the uric acid distribution, as described previously [19].
Where data were available only in separate age strata, a
single pooled estimate was used. Fixed-effect summary
measures were calculated as the inverse-variance weighted
average of the log-relative risks. Heterogeneity was assessed
by the heterogeneity Q statistic and by random effect
regression models with restricted maximum likelihood
estimation. Subsidiary analyses (conducted only on studies
known to exclude individuals with existing CHD) grouped
studies by sex, study size, geographical location, sampling
Table 2. Baseline Characteristics of Cases and Controls in the Reykjavik Study
Category Characteristic Cases (n = 2,459) Controls (n = 3,969) p Value
Demographic Age (y) 55.8 (9.3) 55.7 (9.1) Matched
Male, n (%) 1,774 (72) 2,743 (69) Matched
Questionnaire Current smokers (including cigarettes, cigars, pipe), n (%) 1,417 (58) 1,941 (49) , 0.001
Current cigarette smokers, n (%) 962 (39) 1,266 (32) , 0.001
History of diabetes, n (%) 83 (3) 63 (2) , 0.001
Nonmanual occupation
a, n (%) 703 (40) 1,227 (42) 0.15
Education beyond high school
b, n (%) 354 (27) 645 (30) 0.12
Home owner
c, n (%) 1,962 (84) 3,201 (85) 0.39
House: Lives in apartment block
d, n (%) 1,186 (53) 1,833 (50) 0.09
Physical measurements Height (m) 1.71 (0.09) 1.72 (0.09) 0.07
Weight (kg) 76 (14) 75 (14) , 0.001
Body mass index (kg/m
2) 26 (3.9) 25 (3.7) , 0.001
Systolic blood pressure (mm Hg) 146 (22) 141 (20) , 0.001
Diastolic blood pressure (mm Hg) 89 (11) 87 (11) , 0.001
Forced expiratory volume (l/s) 2.8 (0.85) 2.9 (0.86) 0.002
Protein or sugar present in urine, n (%) 112 (5) 102 (3) , 0.001
Blood sample Serum uric acid (lmol/l)
e 312 (73) 300 (66) , 0.001
Total serum cholesterol (mmol/l) 6.82 (1.18) 6.40 (1.14) , 0.001
Serum triglycerides (mmol/l)
f 1.19 (0.79) 1.03 (0.62) , 0.001
Fasting glucose (mmol/l) 4.6 (1.1) 4.5 (0.8) , 0.001
Serum creatinine (lmol/l) 77 (14) 75 (13) , 0.001
Hemoglobin (mmol/l) 9.2 (0.80) 9.1 (0.81) , 0.001
Hematocrit (%) 45 (3.6) 44 (3.5) , 0.001
Inflammatory markers C-reactive protein (mg/l)
f 1.75 (5.3) 1.28 (5.2) , 0.001
von Willebrand factor (IU/dl)
f 107.4 (48) 103.2 (46) , 0.001
Erythrocyte sedimentation rate (mm/first h)
f 7.4 (10.6) 6.3 (9.7) , 0.001
Values are mean (SD) unless indicated otherwise.
a Information on occupation was available for only 1,742 cases and 2,888 controls, respectively.
b Information on education was available for only 1,292 cases and 2,157 controls, respectively.
c Information on home ownership was available for 2,323 cases and 3,754 controls, respectively.
d Information on type of residence was available for 2,258 cases and 3,646 controls, respectively. Other categories included ‘‘duplex’’ and ‘‘villa.’’
e Information on serum uric acid was available for 2,456 cases and 3,962 controls, respectively.
f Value log transformed for analysis and presented as geometric mean (SD).
DOI: 10.1371/journal.pmed.0020076.t002
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Serum Uric Acid: Prospective Studyframework (population- or workforce-based), degree of
adjustment for other cardiovascular risk factors, type of
assay, and duration of follow-up. Statistical analyses were
conducted using Stata version 7.0. To make some allowance
for multiple comparisons, 99% CI were used for individual
studies, and 95% CI were reserved for the combined
estimates.
Results
The Reykjavik Study
The mean age at CHD event among cases was 70.2 (SD, 9.7)
y. There were highly signiﬁcant differences between cases and
controls with respect to established vascular risk factors such
as smoking, body mass index, blood pressure, and serum lipid
concentrations (Table 2). Serum uric acid values were highly
signiﬁcantly associated with male sex, nonmanual occupation,
body mass index, diastolic blood pressure, triglycerides, and
serum creatinine (p , 0.0001 for each), although most of
these associations weakened after adjustment for other
vascular risk factors (Table S1). In 379 participants who
provided paired blood samples, on average about 12 y apart,
the within-individual correlation coefﬁcient among serum
uric acid values was 0.60 (CI, 0.54–0.66), similar to the decade-
to-decade consistency observed in values of systolic blood
pressure [0.66 (CI, 0.60–0.72)] and total serum cholesterol
[0.60 (CI, 0.54–0.66)] in these participants.
The odds ratio for CHD was 1.39 (CI, 1.20–1.61; Wald test
statistic, v
2
1 = 18.4) in males in the top third compared with
those in the bottom third of baseline serum uric acid levels
(tertile cut-offs, . 339 versus , 286 lmol/l [Table 3]), and this
fell to 1.12 (CI, 0.94–1.33; v
2
1 = 1.5) after adjustment for
smoking, other established risk factors, and indicators of
socioeconomic status (Table 3). The odds ratio for CHD was
1.42 (CI, 1.13–1.79; v
2
1 = 9.1) in females in the top third
compared with those in the bottom third of baseline serum
uric acid levels (tertile cut-offs, . 280 v , 232 lmol/l), and
this fell to 1.12 (CI, 0.85–1.46; v
2
1 = 0.6) after adjustment for
smoking, other established risk factors, and indicators of
socioeconomic status. In a combined analysis of males and
females, the odds ratio for CHD was 1.39 (CI, 1.23–1.58; v
2
1 =
27.2) and this fell to 1.12 (CI, 0.97–1.30; v
2
1 = 2.4) after
adjustment. In analyses restricted to the 2,083 cases without
evidence of CHD at baseline, the adjusted odds ratios fell
further to 1.08 (CI, 0.90–1.31) in males and 1.00 (CI, 0.75–1.33)
in females (Table 3), but the ﬁndings were materially
unchanged in analyses excluding the 200 CHD cases with
‘‘possible’’ MI or in analyses varying cut-off levels (e.g., by
quarters, ﬁfths, or increases of 1 SD; see Table 3 legend).
Figure 1 indicates that there was no substantial variation in
the strength of association between serum uric acid and CHD
at different levels of established risk factors, and, in
particular, there was no good evidence of interactions with
sex or systolic blood pressure (sex, v
2
1 = 0.03, p = 0.86;
smoking, v
2
1 = 0.28, p = 0.60; body mass index, v
2
2 = 1.13, p
= 0.57; total cholesterol, v
2
2 = 2.42, p = 0.30; systolic blood
pressure, v
2
2 = 4.63, p = 0.10).
Table 3. Relative Odds of Coronary Heart Disease in Individuals Who Had Serum Uric Acid in the Top Third of the Sex-Specific
Distribution of Controls Relative to Those Who Had Values in the Bottom Third of This Distribution in the Reykjavik Study
Participants
in Analyses
Cut-Off
Levels Used
Number of Cases Number of Controls Odds Ratio (95% CI) Adjusted For:
Top Middle Bottom Top Middle Bottom Age
and
Period
Age,
Period, and
Smoking
Age, Period,
Smoking,
and Risk
Factors
a,b
Age, Period
Smoking, Risk
Factors
a, and
Socioeconomic
Status
All 2,456 cases and
3,962 controls
Serum uric acid
in males
(339 and 286 lmol/l)
646 608 519 854 949 933 1.39
(1.20–1.61)
1.44
(1.24–1.68)
1.12
(0.94–1.33)
1.12
(0.94–1.33)
Serum uric acid
in females
(280 and 232 lmol/l)
264 201 218 393 377 456 1.42
(1.13–1.79)
1.49
(1.18–1.89)
1.11
(0.85–1.44)
1.12
(0.85–1.46)
Serum uric acid
in males and
females combined
910 809 737 1,247 1,326 1,389 1.39
(1.23–1.58)
1.45
(1.28–1.65)
1.11
(0.96–1.29)
1.12
(0.97–1.30)
2,080 cases and
3,962 controls without
evidence of coronary
heart disease at entry
Serum uric acid
in males
(339 and 286 lmol/l)
523 521 444 854 949 933 1.34
(1.14–1.57)
1.39
(1.18–1.63)
1.07
(0.89–1.29)
1.08
(0.90–1.31)
Serum uric acid
in females
(280 and 232 lmol/l)
211 185 196 393 377 456 1.26
(0.99–1.61)
1.34
(1.04–1.71)
0.98
(0.74–1.30)
1.00
(0.75–1.33)
Serum uric acid
in males and
females combined
734 706 640 1,247 1,326 1,389 1.31
(1.15–1.50)
1.37
(1.20–1.57)
1.04
(0.89–1.21)
1.06
(0.90–1.23)
a Systolic blood pressure, total cholesterol, triglycerides, body mass index, smoking (former or current, including number cigs per day), FEV1, history of diabetes
b Odds ratios (males and females combined) using alternative comparisons were: 1.24 (0.99–1.55) top fifth vs. bottom fifth; 1.22 (1.03–1.45) top quarter vs. bottom quarter; 1.08 (1.02–1.15) per standard deviation increase. Sex-specific odds
ratios using thirds of the overall (not sex-specific) distribution of serum uric acid were: in males, 1.19 (0.98–1.43); in females 1.34 (0.98–1.82).
DOI: 10.1371/journal.pmed.0020076.t003
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In aggregate, 16 prospective reports [6,14,15,16,17,18,20,21,
22,23,24,25,26,27,28] on serum uric acid (including the
present study) have involved a total of 9,458 CHD cases and
155,084 controls, with a weighted mean age at entry of 50 y
and weighted mean follow-up of 10.5 y (Table 4). Studies were
conducted in the USA [22,23,24,25,28], Western Europe
[6,14,15,17,18,20,27], Israel [21], and Japan [16,26], and all
reported adjustment for at least smoking and some other
established risk factors. Overall, in a comparison of individ-
uals with serum uric acid values in the top third with those in
the bottom third of the population, the relative risk for CHD
was 1.13 (CI, 1.07–1.20: Figure 2), with statistically compatible
results in male and females (v
2
1 = 1.1; p = 0.3). In a
subsidiary analysis of seven studies [20,22,23,24,25,27], involv-
ing 6,357 CHD cases and 65,978 controls, all of which
excluded individuals with known cardiovascular disease at
the baseline examination, the relative risk for CHD was 1.10
(CI, 1.03–1.18). There was signiﬁcant heterogeneity among
the 23 sex-speciﬁc study estimates (v
2
2 = 38.1, p = 0.02), but
only some of this was explained by study characteristics such
as sample size (v
2
2 = 11.1), geographical location (v
2
2 = 1.0),
sampling framework (v
2
1 = 0.5), degree of adjustment for
possible confounders (v
2
2 = 10.0), duration of follow-up (v
2
1
= 0.1), and assay type (v
2
3 = 4.2) (Figure 3). In a random-
effects model, that takes additional account of study variation
and the joint impact of these characteristics, only degree of
adjustment for possible confounders remained a signiﬁcant
source of heterogeneity at the 1% level of signiﬁcance (sex, p
= 0.36; sample size, p = 0.41; geographical location, p = 0.71;
sampling framework, p = 0.02; degree of adjustment for
possible confounders, p = 0.001; duration of follow-up, p =
0.67; and assay type, p = 0.06).
Discussion
The present report provides prospective evidence from the
largest study so far of serum uric acid and CHD—plus a meta-
analysis of 15 previous relevant studies—involving a total of
more than 9,000 incident cases and more than 150,000
controls. The overall ﬁndings suggest that individuals with
baseline serum uric acid values in the top third of the
population have about a 10% greater risk of CHD over the
Figure 1. Associations between Serum Uric Acid and CHD in 2,456 cases
and 3,962 Controls in the Reykjavik Study at Different Levels of
Established Risk Factors
Squares indicate odds ratios, with the size of the square proportional
to the effective sample size.
DOI: 10.1371/journal.pmed.0020076.g001
Figure 2. Meta-Analysis of Prospective Observational Studies of Serum Uric Acid and CHD in Essentially General Populations, Subdivided by Sex
Conventions are the same as in Figure 1. Combined odds ratios and their CIs are indicated by unshaded diamonds for subtotals and shaded
diamonds forgrandtotals.þ,adjustmentreported onlyforageand sex;þþ,adjustmentfortheseplussmoking;þþþ,adjustmentfortheseplussome
additionalestablishedriskfactors;þþþþ,adjustmentfortheseplusexistingcardiovasculardisease.Studyabbreviations:ARIC,AtherosclerosisRisk
in Communities; BIRNH, Belgium Interuniversity Research on Nutrition and Health; BRHS, British Regional Heart Study; CHA, Chicago Heart
Association Detection Project in Industry; GRIPS, Go ¨ttingen Risk Incidence and Prevalence Study; IIHDS, Israeli Ischemic Heart Disease Study;
MONICA, World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease; NHANES, National Health and Nutrition
Examination Survey; NHEFS, NHANES I Epidemiologic Follow-Up Study; PROCAM, Prospective Cardiovascular Munster Study.
DOI: 10.1371/journal.pmed.0020076.g002
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Serum Uric Acid: Prospective Studysubsequent decade than those in the bottom third (with the
likelihood that this association would be about twice as strong
if based on long-term usual levels of serum uric acid). It is
likely, however, that this modest association has been
exaggerated by the preferential publication of striking
ﬁndings in smaller studies (‘‘publication bias’’), or by residual
confounding by established risk factors, or both. For example,
the observation of weaker associations in studies with more
comprehensive adjustment for possible confounders lessens
the likelihood that any association between serum uric acid
and CHD is independent from possible confounders; the odds
ratio was only 1.02 (CI, 0.91–1.14), which is not signiﬁcant, in
the eight studies with the most complete reported adjustment
for possible confounders (Figure 3). The present data also
provide no good evidence to support previous claims that the
association between serum uric acid and CHD is stronger in
females than in males [5], or stronger at higher levels of
established risk factors, such as in individuals with higher
blood pressure recordings [29].
The main implication of these data is to refute suggestions
made throughout the past half-century that measurement of
serum uric acid can importantly enhance the prediction of
CHD in general populations. These data do not directly
address the question of whether or not serum uric acid may
be involved in the causation of CHD through a number of
potentially relevant vascular effects (such as through the
formation of free radicals or through the oxidation of low-
density-lipoprotein cholesterol [1,30]), but they suggest that
serum uric acid levels are unlikely to be a major determinant
of CHD.
Supporting Information
Table S1.
Comparison of Baseline Values of Risk Factors and Other Character-
istics in Controls in the Reykjavik Study by Thirds of Serum Uric Acid
Concentration
Found at DOI: 10.1371/journal.pmed.0020076.st001 (67 KB DOC).
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Patient Summary
Background. Defining which risk factors are important for disease is
useful for clinicians and patients not only because the presence of risk
factors allows the prediction of who is more likely to get a disease, but
also because they provide some insight into the underlying causes of
disease. One such suspected risk factor for coronary heart disease is the
level of uric acid in the blood. The debate over whether uric acid is useful
for predicting heart disease has been going on for over fifty years. Most
evidence for risk factors comes from studies of populations, in which it
can be hard to tease out the effects of many different factors; often
studies come to different conclusions. One way of finding out which
results are reliable is to pool the results of many studies.
What Did the Researchers Find? They looked at the uric acid levels of
around 2,500 people with coronary heart disease and almost 4,000
controls measured at the start of a large study in Iceland, and then
investigated whether there was a relation between levels of uric acid and
development of heart disease. After adjusting for all the other factors
that could affect the chance of heart disease, they found that uric acid
did not predict heart disease. They then combined these results with
those from 15 other studies, and confirmed the findings.
What Do These Findings Mean? After fifty years, it now seems clear
that measurement of uric acid does not help to predict heart disease. It
may still be involved in triggering heart disease, but any effect must be
subtle.
Where Can I Get More Information? The National Heart Lung and
Blood Institute has many pages of information on heart disease: http://
www.nhlbi.nih.gov/health/public/heart/index.htm#ami
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